Latent M. tuberculosis infection - pathogenesis, diagnosis, treatment and prevention strategies

• Autorzy: Druszczynska M. , Kowalewicz -Kulbat M. , Fol M. , Wlodarczyk M. , Rudnicka W.
• Języki publikacji: EN

Abstrakty

EN

One third of the earth’s population is infected with Mycobacterium tuberculosis (Mtb), but only 5–10% of the infected individuals develop active tuberculosis (TB) over their lifetime. The remaining 90–95% stay healthy and are called latently infected individuals. They are the biggest reservoir of the tubercle bacilli and identifying the cases of latent TB is a part of the global plan of TB control. From the clinical point of view detection of latent TB infections (LTBI) in individuals with the highest active TB risk including cases of HIV infection, autoimmune inflammatory diseases or cancer, is a priority. This review summarizes the recent findings in the pathogenesis of latent TB, its diagnosis, treatment and prevention.

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2012
• Tom: 61
• Numer: 1
• Opis fizyczny: p.3-10,ref.

Twórcy

autor

Druszczynska M.

• Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland

autor

Kowalewicz -Kulbat M.

autor

Fol M.

autor

Wlodarczyk M.

autor

Rudnicka W.

Bibliografia

• Ahmad S. 2010. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respir. Res. 11: 169–185.
• Arend S.M., W.P. Franken, H. Aggerbeck, C. Prins, J.T. Van Dissel, B. !ierry-Carstensen, P.N. Tingskov, K. Weldingh and P. Anderson. 2008. Double-blind randomized phase I study comparing rsESAT-6 to tuberculin as skin test reagent in the diagnosis of tuberculosis infection. Tuberculosis 88: 249–261.
• Ayub A., S.H. Yale, K.D. Reed, R.M. Nasser and S.R. Gilbert. 2004. Testing for latent tuberculosis. Clin. Med. Res. 3: 191–194.
• Baena A. and S.A. Porcelli. 2009. Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens. 74: 189–204.
• Bhatt K. and P. Salgame. 2007. Host innate immune response to Mycobacterium tuberculosis. J. Clin. Immunol. 4: 347–362.
• Blumberg H.M, M.K. Leonard and R.M. Jasmer. 2005. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 293: 2776–2784.
• Brewer T.F. 2000. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-nalysis of the literature. Clin. Infect. Dis. 31(Suppl 3): S64–67.
• Butera O., T. Chiacchio, S. Carrara, R. Casetti, V. Vanini, S. Meraviglia, G. Guggino, F. Dieli, M. Vecchi, F.N. Lauria, A. Marruchella, P. Laurenti, M. Singh, N. Caccamo, E. Girardi and D. Goletti. 2009. New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. BMC Infect. Dis. 9: 182.
• Cattamanchi A., I. Ssewenyana, J.L. Davis, L. Huang, W. Worodria, S. den Boon, S. Yoo, A. Andama, P.C. Hopewell and H. Cao. 2010. Role of interferon-gamma release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. BMC Infec. Dis. 10: 75–81.
• Carvalho A.C.C., M.C. Pezzoli, I. El-Hamad, P. Arce, S. Bigoni, C. Scarcella, A.M. Indelicato, C. Scolari, G. Carosi and A. Matteelli. 2007. QuantiFERON®-TB Gold test in the identification of latent tuberculosis infection in immigrants. J. Infect. 55: 164–168.
• Chang S.T., J.J. Linderman and D.E. Kirschner. 2005. Multiple mechanisms allow Mycobacterium tuberculosis to continuously inhibit MHC class II-mediated antigen presentation by macrophages. Proc. Natl. Acad. Sci. USA 102: 4530–4535.
• Chen J., R. Zhang, J. Wang, L. Liu, Y. Zheng, Y. Shen, T. Qi and H. Lu. 2011. Interferon-gamma release assays for the diagnosis of active tuberculosis in HIV-infected patients: a systemic review and meta-analysis. PLoS One 6: e26827.
• Co D.O., L.H. Hogan, S.I. Kim and M. Sandor. 2004. Mycobacterial granulomas: keys to a long-lasting host-pathogen relationship. Clin. Immunol. 113: 130–136.
• Colditz G.A., T.F. Brewer, C.S. Berkey, M.E. Wilson, E. Burdick, H.V. Fineberg and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271: 698–702.
• Corbett E.L, T. Bandason, Y.B. Cheung, S. Munyati, P. Godfrey-Fausset, R. Hayes, G. Churchyard, A. Butterworth and P. Mason.2007. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med. 4: e22.
• Daniel T.M. 2006. the history of tuberculosis. Respir Med. 100: 1862–1870.
• Day T.A., M. Koch, G. Nouailles, M. Jacobsen, G.A. Kosmiadi, D. Miekley, S. Kuhlmann, S. Jörg, P. Gamradt, H.J. Mollenkopf, R. Hurwitz, S.T. Reece, S.H. Kaufmann and M. Kursar. 2010. Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosis. Eur. J. Immunol. 40: 1663–1673.
• Denkinger C.M., K. Dheda and M. Pai. 2011. Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion? Clin. Microbiol. Infect. 17: 806–814.
• Diel R., A. Nienhaus, C. Lange, K. Meywald-Walter, M. Forsbohm and T. Schaberg. 2006. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir. Res. 7: 77–85.
• Dilektasil A.G., E. Erdem, E. Durukan and F.Q. Eyüboglu. 2010. Is the T-cell-based interferon-gamma releasing assay feasible for diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country? Jpn. J. Infect. Dis. 63: 433–436.
• Divangahi M., M. Chen, H. Gan, D. Desjardins, T.T. Hickman, D.M. Lee, S. Fortune, S.M. Behar and H.G. Remold. 2009. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat. Immunol. 10: 899–906.
• Druszczynska M., D. Strapagiel, S. Kwiatkowska, M. Kowalewicz-Kulbat, B. Rózalska, M. Chmiela and W. Rudnicka. 2006. Tuberculosis bacilli still posing a threat. Polymorphism of genes regulating anti-mycobacterial properties of macrophages. Pol. J. Microbiol. 55: 7–12.
• Ducati R.G., A. Ruffino-Netto, L.A. Basso and D.S. Santos. 2006. The resumption of consumption – a review on tuberculosis. Mem. Inst. Oswaldo Cruz 101: 697–714.
• Dye C., S. Scheele, P. Dolin, V. Pathania and M.C. Raviglione. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 282:677–686.
• Dyrhol-Riise A.M., G. Gran, T. Wentzel-Larsen, B. Blomberg, C.G. Haanshuus and O. Morkve. 2010. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients form a tuberculosis low-endemic country. BMC Infect. Dis. 10: 57–65
• Flynn J.L., J. Chan, K.J. Triebold, D.K. Dalton, T.A. Stewart and B.R. Bloom. 1993. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178: 2249–2254.
• Flynn J.L., M.M. Goldstein, J. Chan, K.J. Triebold, K. Pfeffer, C.J. Lowenstein, R. Schreiber, T.W. Mak and B.R. Bloom. 1995. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 2: 561–572.
• Gao X.F., L. Wang, G.J. Liu, J. Wen, X. Sun, Y. Xie and Y-P. Li. 2006. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int. J. Tuberc. Lung. Dis. 10: 1080–1090.
• Gideon H.P. and J.L. Flynn. 2011. Latent tuberculosis: what the host “sees”? Immunol. Res. 50: 202–212.
• Guidry T.V., R.L.Jr. Hunter and J.K Actor. 2007. Mycobacterial glycolipid trehalose 6,6’-dimycolate-induced hypersensitive granulomas: contribution of CD4+ lymphocytes. Microbiology 153: 3360–3369.
• Harding J.S., H.A. Schreiber and M. Sandor. 2011. Granuloma transplantation: an approach to study Mycobacterium-host interactions. Front. Microbiol. 2: 245.
• Hesseling A.C., B.J. Marais, R.P. Gie, H.S. Schaaf, P.E. Fine, P. Godfrey-Faussett and N. Beyers. 2007. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25: 14–18.
• Hsia E.C., N. Schluger, J. Cush, R.E. Chaisson, E.L. Matteson, S. Xu, A. Beutler, M.K. Doyle, B. Hsu and M.U. Rahman. 2012. Interferon-gamma release assay versus tuberculin skin test across RA, PsA, and AS patients prior to treatment with golimumab, a human anti-TNF antibody. Arthritis Rheum. doi: 10.1002/art. 34382.
• Kunst H. and K.S. Khan. 2010. Age-related risk of hepatotoxicity in treatment of latent tuberculosis infection: a systematic review. Int. J. Tuberc. Lung. Dis. 14: 1374–1381.
• Lalvani A. 2007. Diagnosing tuberculosis infection in the 21st century. New tools to tackle an old enemy. Chest. 131: 1898–1906.
• Launois P., A. Drowart, E. Bourreau, P. Couppie, C.-M. Farber, J.-P. van Vooren and K. Huygen. 2011. T cell reactivity against mycolyl transferase antigen 85 of M. tuberculosis in HIV-TB coinfected subjects and in AIDS patients su!ering from tuberculosis and nontuberculous mycobacterial infections. Clin. Develop. Immunol. pii: 640309.
• Lillebaek T., A. Dirksen, I. Baess, B. Strunge, V.Ø. Thomsen and A.B. Andersen. 2002. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J. Infect. Dis. 185: 401–404.
• Lin P.L. and J.L. Flynn. 2010. Understanding latent tuberculosis: a moving target. J. Immunol. 185: 15–22.
• Ling D.I., M. Pai, V. Davids, L. Brunet, L. Lenders, R. Meldau, G. Calligaro, B. Allwood, R. van Zyl-Smit, J. Peter, E. Bateman, R. Dawson and K. Dheda. 2011. Are interferon-γ release assays useful for diagnosing active tuberculosis in a high-burden setting? Eur. Respir. J. 38: 649–656.
• Mahairas G.G., P.J. Sabo, M.J. Hickey, D.C. Singh and C.K. Stover. 1996. Molecular analysis of genetic di!erences between Mycobacterium bovis BCG, virulent M. bovis. J. Bacteriol. 178: 1274–1282.
• McMurray D.N. and L.H. Ly. 2009. TB vaccines: the paradigms they are a-shifting. Expert. Rev. Vaccines 8: 1615–1618.
• McShane H. 2009. Vaccine strategies against tuberculosis. Swiss Med. Wkly. 139: 156–160.
• Menzies D., H.A. Jahdali and B.A. Otaibi. 2011. Recent developments in treatments of latent tuberculosis infection. Indian. J. Med. Res. 133: 257–266.
• Milman N., B. Søborg, C.B. Svendsen and A.B. Andersen. 2011. Quantiferon test for tuberculosis screening in sarcoidosis patients. Scand. J. Infect. Dis. 43: 728–735.
• Minguez S., I. Latorre, L. Mateo, A. Lacoma, J. Diaz, A. Olive and J. Dominguez. 2012. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with in:ammatory arthritis scheduled for anti-tumour necrosis factor treatment. Clin. Rheumatol. doi 10.1007/s10067-012-1938-z
• Mori T. 2011. Efficacy of BCG vaccination. pp. 13–45. In: Takii T., Maeyama J. And S. Yamamoto (eds). BCG. Vaccine and adjuvant. Jata Press, Tokyo, Japan.
• Niki M. and S. Matsumoto. 2011. Host and bacterial factors that regulate Mycobacterium tuberculosis infection and persistence. pp. 215–238. In: Takii T., Maeyama J. and S. Yamamoto (eds). BCG. Vaccine and adjuvant. Jata Press, Tokyo, Japan.
• Page K.R., F. Sifakis, R. Montes de Oca, W.A. Cronin, M.C. Doherty, L. Federline, S. Bur, T. Walsh, W. Karney, J. Milman and others. 2006. Improved adherence and less toxicity with rifampin vs isoniazid for the treatment of latent tuberculosis: a retrospective study. Arch. Intern. Med. 166: 1863–1870.
• Peyron P., J. Vaubourgeix, Y. Poquet, F. Levillain, C. Botanch, F. Bardou, M. Daffé, J.F. Emile, B. Marchou, P.J. Cardona, C. de Chastellier and F. Altare. 2008. Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog. 4: e1000204.
• Pai M., A. Zwerling and D. Menzies. 2008. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 149: 177–184.
• Richeldi L. 2006. An update the diagnosis of tuberculosis infection. Am. J. Respir. Crit. Care. Med. 174: 736–742.
• Santin M., S. Casas, M. Saumoy, A. Andreu, R. Moure, F. Alcaide, E. Ferrer and D. Podzamczer. 2011. Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-γ release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagn. Microbiol. Infect. Dis. 69: 59–65.
• Saunders B.M. and A.M. Cooper. 2000. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol. Cell. Biol. 78: 334–341.
• Sester M., G. Sotgiu, C. Lange, C. Giehl, E. Girardi, G.B. Migliori, A. Bossink, K. Dheda, R. Diel, J. Dominiguez, M. Lipman, J. Nemeth, P. Ravn, S. Winkler, E. Huitric, A. Sandgren and D. Manissero. 2011. Interferon-γ release assay for the diagnosis of active tuberculosis: a systemic review and meta-analysis. Eur. Respire. J. 37: 100–111.
• Singh M., A.G. Saini, N. Anil and A. Aggarwal. 2011. Latent tuberculosis in children: diagnosis and management. Indian. J. Paediatr. 78: 464–468.
• Stefan D.C., A. Dippenaar, A.K. Detjen, H.S. Schaaf, B.J. Marais, B. Kriel, L. Loebenberg, G. Walzl and A.C. Hesseling. 2010. Interferon-gamma release assays for the detection of Mycobacterium tuberculosis infection in children with cancer. Int. J. Tuberc. Lung. Dis. 14: 689–694.
• Stein C.M., S. Zalwango, L.L. Malone, S. Won, H. Mayanja-Kizza, R.D. Mugerwa, D.V. Leontiev, C.L. !ompson, K.C. Cartier, R.C. Elston, S.K. Iyengar, W.H. Boom, and C.C. Whalen. 2008. Genome scan of M. tuberculosis infection and disease in Ugandans. PLoS One. 3:e4094
• Teutschbein J., G. Schumann, U. Möln, S. Grabely, S.T. Cole and T. Munder. 2009. A protein linkage map of the ESAT-6 secretion system 1 (ESX-1) of Mycobacterium tuberculosis. Microbiol. Res. 164: 253–259.
• Turner J., M. Gonzalez-Juarrero, B.M. Saunders, J.V. Brooks, P. Marietta, D.L. Ellis, A.A. Frank, A.M. Cooper and I.M. Orme. 2001. Immunological basis for reactivation of tuberculosis in mice. Infect Immun. 69: 3264–3270.
• van Pinxteren I.A.H., P. Ravn, E.M. Agger, J. Pollock and P. Andersen. 2000. Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin. Diagn. Lab. Immunol. 7: 155–160.
• Vittor A.Y., J.M. Garland and D. Schlossberg. 2011. Improving the diagnosis of tuberculosis: from QuantiFERON to new techniques to diagnose tuberculosis infections. Curr. HIV/AIDS Rep. 8: 153–163.
• Vynnycky E. and P.E. Fine. 2000. Lifetime risks, incubation period, and serial interval of tuberculosis. Am. J. Epidemiol. 152: 247–263.
• Wagner R. 1964. Clemens von Pirquet, discoverer of the concept of allergy. Bull. NY Acad. Med. 40: 229–235.
• Wallis R.S., M. Pai, D. Menzies, T.M. Doherty, G. Walzl, M.D. Perkins and A. Zumla. 2010. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 375: 1920–1937.
• Walzl G., K. Ronacher, W. Hanekom, T.J. Scriba and A. Zumla. 2011. Immunological biomarkers of tuberculosis. Nat. Rev. Immunol. 11: 343–354.
• Weldingh K. and P. Andersen. 2008. ESAT-6/CFP10 skin test predicts disease in M.tuberculosis-infected guinea pigs. PloS ONE 3: e1978.
• WHO. 2007. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec. 82: 193–196.
• WHO. 2010. Immunization surveillance, assessment and monitoring. http://www.who.int/immunization_monitoring/diseases/tuberculosis.
• WHO. 2010. Global Tuberculosis Control 2010. Available at http:// www. whqlibdoc.who.int/publications/2010/9789241564069_eng.
• Wu X., L. Zg, J. Zhang, C. Zg, L. Zhu and Y. Shi. 2008. Recombinat early secreted antigen target protein as a skin test antigen for the specific detection of Mycobacterium tuberculosis infection. Clin. Exp. Immunol. 152: 81–87.
• Zhang S., L. Shao, L. Mo, J. Chen, F. Wang, C. Meng, M. Zhong, L. Qiu, M. Wu, X. Weng, and W. Zhang. 2010. Evaluation of gamma interferon release assays using Mycobacterium tuberculosis antigens for diagnosis of latent and active tuberculosis in Mycobacterium bovis BCG-vaccinated populations. Clin. Vaccine. Immunol. 17: 1985–1990.

Uwagi

PL

Rekord w opracowaniu